Gemalto to penetrate biometrics authentication market with its acquisition of 3M Cogent
Category: #world  By Saipriya Iyer  Date: 2017-05-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gemalto to penetrate biometrics authentication market with its acquisition of 3M Cogent

Gemalto, the global leader in digital security has closed its acquisition with 3M’s identity management business – including the subsidiary of 3M Cogent Inc., one of the leading players of global fingerprint biometrics machine market, which provides a full spectrum of biometric solutions for border control, law enforcement, and civil identification.

The transaction, worth approximately USD 850 million, will enable Gemalto to take control over 3M’s three main portfolios, and will also help add security features to Gemalto’s Government Programs offering. With this strategic move, Gemalto is set to in-source a document reader line, 3M’s internal secure identity materials business, and the entire subsidiary of 3M Cogent with its unique biometric authentication solutions.

Back in 2016, 3M’s identity management unit generated revenue worth USD 202 million with an approximate profit margin of USD 53 million.

One of Gemalto’s top executives deems that this collaboration of 3M’s Identity Management Business and Gemalto will bring together the market access, expertise, and advanced technologies of both the firms under one roof. It has also been stated that this deal is a strategic move, which will allow Gemalto to develop and provide biometric authentication solutions for a digitized world. 

Gemalto’s software solutions are programmed efficiently to authenticate transactions, people and objects, encrypt data, and provide secure digital services to their billions of customers across over 180 countries.

A company press release from late 2016 reported that roughly around 450 members of 3M’s experienced and highly-skilled team were likely to make a transit to Gemalto after the completion of the acquisition in the first half of 2017.

This move has also ideally positioned the company to provide effective solutions for the expanding commercial biometrics market. 3M Cogent offers biometric hardware & software products that will now become an integral part of Gemalto’s portfolio and will apparently be used for authentication and identity verification. These biometric software solutions, biometric readers, and scanners are likely to deliver novel options to Gemalto’s customers across the globe.

The commercialization of biometrics technology has witnessed quite a commendable upsurge which is evident from its heavy deployment across the various end-use sectors. Experts predict that Gemalto is likely to garner huge profits with the growing popularity of mobile and online transactions. A report depicts that through the acquired business, the company is estimated to grow at rate of over 10% with EBITDA margins more than 20% by 2020.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...